Frontlight ResearchEarly access
CompletedPhase 2
A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses
Key facts
- Who runs it
- Centre Hospitalier Universitaire de Nice
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 8 people enrolled
- Started
- 18 Mar 2024
- Ended
- 18 Aug 2026
- Type of study
- Interventional
- Treatments tested
- deucravacitinib
- Record updated
- 16 October 2026
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Subject has congenital skin fragility with skin and/or mucosal blisters, a clinical phenotype of EBS-sev and a laboratory confirmed diagnosis of EBS by KRT5 and/or 14 mutation (autosomal only) OR a clinical phenotype of inflammatory ichthyosis (IC) including keratinopathic ichthyosis due to KRT1/10 mutation, ECI with identified genetic mutations (TGM5, NIPAL4, ABCA12, etc…)
- Subject has at least a mean daily number of 4 new blisters (EBS-sev) OR an ISS > 50/128; Subject agrees not to use any topical therapies other than the investigator approved
Who cannot take part
- Medical History and Concurrent Diseases
- Subjects with another form of ICI ie Netherton syndrome, Kid syndrome etc
- Infectious/Immune-related Exclusions
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn about deucravacitinib treatment in adults with inflammatory epidermal genodermatoses . The main question it aims to answer are: describe efficacity and safety of this treatment.
Read full original descriptionShow less
Participants will take treatments and have to use bullets during the study period.
The group in the trial
- deucravacitinib treatmentTreatment being tested
challenge-dechallenge -rechallenge design
Treatment: deucravacitinib
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 16 October 2026